Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

about

Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

P2860

Q30699740-9F18B275-ED9E-4A15-83BF-F4BB8A904C4B Q40957502-CEE6BCA3-66CE-4CF1-A66E-A2BAF3E3FB7E

P2860

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

Item

http://www.wikidata.org/entity/Q38116451

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

@en

type

Item

label

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

@en

prefLabel

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

@en

P1476

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

@en

P2093

Clemens Warnke

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

P2888

s00702-013-1055-4

P304

S55-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00702-013-1055-4

http://www.w3.org/2001/XMLSchema#string

P478

120 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Hartung

Bernd C Kieseier

P577

2013-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23793997

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

about

P2860

P2860

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P698

P921